# KEYNOTE-062 (NCT02494583)

> Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab
- Indication: first-line advanced gastric or gastroesophageal junction adenocarcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02494583
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Gastric Adenocarcinoma
- Interventions: Pembrolizumab; Cisplatin; 5-FU; Capecitabine; Placebo
- Enrollment: 763
- Primary outcome: Pembro Combo vs SOC: Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With PD-L1 CPS ≥1 (All Participants)
- Primary outcome: Pembro Combo vs SOC: Overall Survival (OS) in Participants With PD-L1 CPS ≥1 (All Participants)
- Primary outcome: Pembro Combo vs SOC: OS in Participants With PD-L1 CPS ≥10
- Primary outcome: Pembro Mono vs SOC: OS in Participants With PD-L1 CPS ≥1 (All Participants)
- Primary outcome: Pembro Mono vs SOC: OS in Participants With PD-L1 CPS ≥10

## Indexed commentary on KEYNOTE-062 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 42 posts on X
- 4 podcast episodes
- 1 YouTube video

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=keynote-062-nct02494583

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02494583", "email": "<work email>"}; the inbox owner confirms by the emailed link.